← All trials
NCT04818099
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2020
- Primary completion
- Oct 10, 2023
- Completion date
- Apr 1, 2024
- First posted
- Mar 26, 2021
- Last posted
- Mar 26, 2021
- Enrollment
- 208
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Guangzhou Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.